Search results
Showing 76 to 90 of 974 results for death
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) and chemotherapy for untreated metastatic non-small-cell lung cancer.
Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)
Evidence-based recommendations on sodium zirconium cyclosilicate (Lokelma) for treating hyperkalaemia in adults.
Evidence-based recommendations on dabrafenib (Finlee) with trametinib (Spexotras) for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over.
Evidence-based recommendations on implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) for arrhythmias and heart failure
Early value assessment (EVA) guidance on CaRi-Heart for predicting cardiac risk in suspected coronary artery disease....
Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults.
Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults.
77 people die Death and disability 1 year after the stroke in people over 60 Death and disability with decompressive...
moderate disability 12 people survive with severe disability 63 people die Death and disability 1 year after the stroke in people under...
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)
Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older.
Asfotase alfa for treating paediatric-onset hypophosphatasia (HST23)
Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in babies, children, young people and adults.
Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia (TA119)
Evidence-based recommendations on fludarabine monotherapy for untreated chronic lymphocytic leukaemia in adults.
Implanting a baroreceptor stimulation device for resistant hypertension
In development [GID-IP1180] Expected publication date: TBC
In development [GID-NG10182] Expected publication date: TBC
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma (TA858)
Evidence-based recommendations on lenvatinib (Kisplyx) with pembrolizumab (Keytruda) for untreated advanced renal cell carcinoma in adults.